Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 2012

View Archived Issues

Scientists at Merck & Co. present novel phosphodiesterase 10A inhibitors

Pfizer patents novel acetyl-CoA carboxylase inhibitors

New data disclosed on first PI3Kalpha-specific anticancer agent to enter clinic

New candidate cancer drugs discovered at Bristol-Myers Squibb

New insulin secretagogues designed in Japan

Pathway Therapeutics discloses novel PI3K/mTOR inhibitors

Lucassin approved in Australia

Chinese study yields potential biomarker of PAH severity due to heart disease

Novel data presented on launched antiepileptic at ongoing AAN meeting

Troponin activator shows promise in patients with ALS

Astellas and Drais enter partnership for candidate ulcerative colitis drug

Compugen validates two new products in autoimmune disease models

Dainippon Sumitomo Pharma completes acquisition

FDA extends review date for Relistor sNDA

Watson Pharmaceuticals announces plan for strategic acquisition

Takeda receives complete response letter for alogliptin product NDAs

Kythera Biopharmaceuticals reports on European ATX-101 studies

Eisai reports launch of Halaven in Canada

Reimbursement allows early availability of Scenesse in Switzerland

Abbott research results in new potential analgesics

New phase III data support use of levomilnacipran for MDD

Dosing complete in phase IIb blisibimod study

New Ranbaxy combination drug for malaria launched first in India

Boston Scientific stent system set for launch in Canada

First-in-human data confirm safety of Repligen product for spinal muscular atrophy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...